---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence. Covers STOP-HAE, ADX-324-101, ADX-324-302, OASIS-HAE, OASISplus, HELP, and 3 further headings. 267 evidence topics quoted from 52 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 STOP-HAE

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Registry brief summary

> “This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema.”
> “The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.1-2"></a>

###### Primary and secondary objectives

> “The primary objective of the Phase 3 study is to evaluate the efficacy of onvuzosiran in preventing HAE attacks in patients with HAE.”
> “The secondary objective is to characterize the effects of onvuzosiran on the quality and pattern of HAE attacks”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.1-3"></a>

###### UK ethics summary: study aim

> “This study will evaluate how effective ADX-324 is in preventing HAE attacks compared with a placebo (a similar looking 'drug' with no active medications) in participants with HAE.”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/stop-hae-a-phase-3-study-of-adx-324-in-hae/)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Registry dates and number of locations

> “Study Start (Actual) 2025-08-28 Primary Completion (Estimated) 2027-11-30 Study Completion (Estimated) 2027-12-31”
> “This study has 70 locations”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.2-2"></a>

###### Trial initiation, planned sites, and topline timing

> “In August 2025, we initiated our Phase 3 STOP-HAE clinical trial.”
> “Approximately 90 participants with Type I or Type II HAE will be enrolled in 70 global sites.”
> “STOP-HAE enrollment is ongoing, with topline data expected by the end of 2027.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.2-3"></a>

###### First participant dosed

> “today announced that the first patient has been dosed in its Phase 3 STOP-HAE clinical trial evaluating ADX-324 in patients with hereditary angioedema (HAE).”

Source: [ADARx Pharmaceuticals (2025)](https://www.adarx.com/adarx-pharmaceuticals-announces-first-patient-dosed-in-phase-3-stop-hae-clinical-trial-and-orphan-drug-designation-for-adx-324-a-long-acting-sirna-in-development-for-the-prophylactic-treatment-of-her/)

<a id="topic-3.1.1.2-4"></a>

###### Sites and countries reported at EAACI 2026

> “at least 60 sites in 22 countries”
> “First patient dosed in Q4 2025.”

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-3.1.1.2-5"></a>

###### UK research ethics committee opinion

| Field | Reported value |
| --- | --- |
| REC reference | “25/NE/0161” |
| Date of REC opinion | “16 Oct 2025” |
| REC opinion | “Further Information Favourable Opinion” |

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/stop-hae-a-phase-3-study-of-adx-324-in-hae/)

<a id="topic-3.1.1.2-6"></a>

###### French trial sites

> “Centre Hospitalier Universitaire Grenoble Alpes”
> “Centre Hospitalier Universitaire De Nice”
> “Centre Hospitalier Regional Universitaire De Tours”

Source: [Santé.fr (2026)](https://www.sante.fr/essais-cliniques/2025-521352-38-00/stop-hae-etude-de-phase-iii-randomisee-en-double-aveugle-et-controlee-par-placebo-evaluant-l-action-de-l-adx-324-un-sirna-ciblant-la-prekallikreine-chez-des-participants-atteints-d-angio-oedeme-hereditaire)

<a id="topic-3.1.1.2-7"></a>

###### Topline data timing at the Q3 2026 update

> “Onvuzosiran (PKK): Phase 3 STOP-HAE topline data by year-end 2027”

Source: [ADARx Pharmaceuticals third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458321/adrx-ex99_1.htm)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Registry design details

| Field | Reported value |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Model description | “Randomized, double-blind, placebo-controlled study” |
| Masking | “Quadruple” |
| Masking description | “Double blinded” |

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.3-2"></a>

###### Washout, screening, and randomization

> “In this trial, participants undergo a washout of previous long term prophylaxis treatment and then enter a 4-week screening window where baseline HAE attack rate is measured, and then randomized to either 300mg Q6M, 240 mg Q3M or placebo.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.3-3"></a>

###### Randomization ratio, stratification, and visit schedule

> “Randomization (1:1:1)”
> “Stratified by monthly HAE attacks rate”
> “Screening period (up to 8 weeks)”
> “Screening, Day 1 (Dose 1), W3, W5, W9, W13 (Dose 2), W17, W21, W25 (EoS)”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.1.3-4"></a>

###### Post-dose visits and study duration

> “After the start of study drug administration, participants will return to the hospital for 7 post-dose visits at 2- or 4-week intervals for effectiveness and safety tests for 6 months.”
> “The study ends upon completion of the 6 month visits.”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/stop-hae-a-phase-3-study-of-adx-324-in-hae/)

<a id="topic-3.1.1.3-5"></a>

###### Participant timeline on the trial website

> “Screening – 4 to 8 weeks”
> “Study and follow-ups – 25 weeks”
> “The initial study, STOP-HAE, will take approximately 7-8 months to complete.”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="topic-3.1.1.3-6"></a>

###### Transition to the long-term extension

> “A long-term extension clinical trial will further evaluate open-label onvuzosiran treatment for up to three years, with, after 6 months, all participants (including placebo patients from STOP-HAE) moved onto active drug in the open label long term follow up.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.3-7"></a>

###### Regulatory input on the phase 3 design

> “Positive feedback from FDA to move forward with Phase 3 STOP-HAE study.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Registry key inclusion criteria

> “Age ≥18 years at the time of signing informed consent.”
> “Have a documented diagnosis of HAE-1/HAE-2 (Type I or II)”
> “Experience ≥1 Investigator-confirmed HAE attack in the first 4 weeks of Screening or ≥2 Investigator-confirmed HAE attacks in 8 weeks of Screening”
> “Able to use at least one acute therapy to treat HAE attacks (such as a plasma-derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.4-2"></a>

###### Registry key exclusion criteria

> “Concurrent diagnosis of another form of recurrent angioedema (such as acquired angioedema, HAE with normal C1-INH (previously known as HAE Type III), idiopathic angioedema, or recurrent angioedema associated with urticaria).”
> “Any clinically significant renal disease”
> “Any clinically significant hepatic disease”
> “Received prior treatment with any RNA/DNA-based therapy for HAE or intolerant to any prior RNA/DNA-based therapy for any condition, excluding vaccines.”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.4-3"></a>

###### Registry washout periods for long-term prophylaxis

> “C1-INH agent (CINRYZE, HAEGARDA, RUCONEST) within 2 weeks prior to Screening.”
> “Berotralstat (ORLADEYO) within 3 weeks prior to Screening.”
> “Lanadelumab (TAKHZYRO) within 8 weeks prior to the Screening.”
> “Androgen use within 12 weeks prior to Screening.”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.4-4"></a>

###### EU record: laboratory criteria for the HAE diagnosis

> “Avoir un diagnostic documenté d’HAE-1 ou d’HAE-2 reposant sur l’ENSEMBLE des critères suivants (a, b ET c)”
> “Taux d’antigène C1-INH < 50 % de la limite inférieure de la normale (LIN).”
> “Niveau fonctionnel de C1-INH < 50 % de la LIN.”

Source: [Santé.fr (2026)](https://www.sante.fr/essais-cliniques/2025-521352-38-00/stop-hae-etude-de-phase-iii-randomisee-en-double-aveugle-et-controlee-par-placebo-evaluant-l-action-de-l-adx-324-un-sirna-ciblant-la-prekallikreine-chez-des-participants-atteints-d-angio-oedeme-hereditaire)

<a id="topic-3.1.1.4-5"></a>

###### EU record: suitability for on-demand treatment alone

> “Les participants doivent être jugés médicalement aptes à suivre un traitement à la demande comme seule prise en charge médicamenteuse.”

Source: [Santé.fr (2026)](https://www.sante.fr/essais-cliniques/2025-521352-38-00/stop-hae-etude-de-phase-iii-randomisee-en-double-aveugle-et-controlee-par-placebo-evaluant-l-action-de-l-adx-324-un-sirna-ciblant-la-prekallikreine-chez-des-participants-atteints-d-angio-oedeme-hereditaire)

<a id="topic-3.1.1.4-6"></a>

###### EU record: renal function, ACE inhibitors, estrogens, and prior RNA therapy

> “une insuffisance rénale sévère (IRC de stade 3, DFG estimé < 60 ml/min/1,73 m² ; antécédents de syndrome néphrotique)”
> “Inhibiteurs de l’ECA au cours des 4 semaines précédant le dépistage.”
> “Nouvelle prise ou augmentation de la dose de médicaments contenant des œstrogènes et à absorption systémique (tels que les contraceptifs oraux ou le traitement hormonal substitutif) au cours des 3 mois précédant le dépistage.”
> “A déjà reçu un traitement par une thérapie à base d’ARN ou d’ADN pour l’AOH (y compris l’ADX-324)”

Source: [Santé.fr (2026)](https://www.sante.fr/essais-cliniques/2025-521352-38-00/stop-hae-etude-de-phase-iii-randomisee-en-double-aveugle-et-controlee-par-placebo-evaluant-l-action-de-l-adx-324-un-sirna-ciblant-la-prekallikreine-chez-des-participants-atteints-d-angio-oedeme-hereditaire)

<a id="topic-3.1.1.4-7"></a>

###### Acute medication access and washout timing

> “Access to acute medication(s) for attacks provided for all study participants”
> “LTP washout must be completed before Screening, if applicable”

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-3.1.1.4-8"></a>

###### Trial website criteria: prophylaxis discontinuation, medical history, and eDiary

> “Be willing to stop any long-term, preventative medication used to prevent attacks”
> “Have no significant medical history that could interfere with the study (for example, hypertension, diabetes or cardiovascular disease)”
> “Have a mobile phone to register and set up your eDiary account”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Registry interventions

| Intervention | Reported description |
| --- | --- |
| ADX-324 | “siRNA duplex oligonucleotide” |
| Placebo | “saline” |

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.5-2"></a>

###### Randomized treatment groups and injection volumes

| Treatment group | Reported value |
| --- | --- |
| Onvuzosiran every 6 months | “ADX-324 300 mg Q6M (1.5ml)” |
| Onvuzosiran every 3 months | “ADX-324 240 mg Q3M (1.2ml)” |
| Placebo, larger volume | “Placebo (1.5 ml) n=15” |
| Placebo, smaller volume | “Placebo (1.2 ml) n=15” |

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.1.5-3"></a>

###### Blinded dosing on Day 1 and Week 13

> “Participants will be randomly assigned to 1 of 3 treatment groups. 1) ADX-324 300mg on day 1 (D1) + Placebo on Week 13 (W13), 2) ADX-324 240mg D1 + ADX-324 240mg W13, 3) Placebo D1 + Placebo W13.”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/stop-hae-a-phase-3-study-of-adx-324-in-hae/)

<a id="topic-3.1.1.5-4"></a>

###### Dose selection relative to the phase 2a doses

> “Phase 3 dose cohorts: 300 mg Q6M or 240 mg Q3M”
> “The attack-free interval seen with these subtherapeutic doses supported our choice of doses in our ongoing STOP-HAE Phase 3 trial.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.5-5"></a>

###### Pharmacodynamic target for the 300 mg dose

> “supporting the Phase 3 target >80% PKK-KK reduction throughout 6 months in HAE patients at the 300 mg dose”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.1.5-6"></a>

###### Number of active doses during the controlled period

> “Depending on your dosing schedule, you may only have to receive one dose of the investigational drug in this period.”
> “You will not know which group you are assigned to.”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="topic-3.1.1.5-7"></a>

###### On-demand treatment and home nursing visits

> “You will be able to take your on-demand, rescue medication if you experience an attack.”
> “While in the study, participants who choose to take part may be able to also opt-in to having home nursing visits if your trial doctor agrees.”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Monthly HAE Attack Rate as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoint: registry definition

> “The time-normalized number of Investigator-confirmed HAE attacks per month for ADX-324 Dose Level 1 vs placebo”
> “Day 22 to Week 25”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.6.1-2"></a>

###### Exclusion of attacks before Day 22

> “Per feedback from the FDA, HAE attacks before Day 22 will be excluded from primary endpoint analysis, consistent with the siRNA proposed mechanism of action.”
> “One known feature of siRNA therapeutic candidates such as onvuzosiran is lag time of about 22 days between initial treatment and full inhibition.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.6.1-3"></a>

###### Attack recording by daily eDiary

> “using a daily eDiary to report HAE attacks, should these occur”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="topic-3.1.1.6.1-4"></a>

###### Guideline treatment goal: absence of attacks

> “We recommend that the goals of treatment are to achieve total control of the disease and to normalize patients' lives.”
> “Complete control of their disease, for HAE patients, translates to no longer having attacks.”
> “These treatments significantly reduce attack rates, and many patients achieve complete response.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-3.1.1.6.1-5"></a>

###### Phase 2a relationship between prekallikrein suppression and attacks

> “We also correlated the episodes of attack with the PKK levels and found that no attacks occurred when the PKK suppression was >80%, suggesting that >80% suppression is potentially needed to achieve a maximal attack-free state.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.6.1-6"></a>

###### Sponsor target profile for attack outcomes

> “Our target profile for onvuzosiran is to reach greater than 90% reduction in monthly attacks, with greater than 75% of patients achieving attack-free status, on Q3M or Q6M dosing schedule.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.6.1-7"></a>

###### Secondary endpoints: registry definitions

> “The time-normalized number of Investigator-confirmed HAE attacks per month for ADX-324 Dose Level 2 vs placebo”
> “The time-normalized number of Investigator-confirmed HAE attacks requiring acute HAE therapy per month for ADX-324 vs placebo.”
> “The time-normalized number of moderate or severe Investigator confirmed HAE attacks per month for ADX 324 vs placebo.”
> “The proportion of participants who have not experienced an Investigator-confirmed HAE attack (HAE attack-free) for ADX 324 vs placebo.”
> “The proportion of participants with a clinical response defined as a ≥50%, ≥70%, or ≥90% reduction from baseline in Investigator-confirmed HAE attack rate for ADX 324 vs placebo.”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.6.1-8"></a>

###### Patient-reported outcomes: AECT and AE-QoL

> “In addition, efficacy, PK activity, PD activity and patient-reported health-related quality of life (AECT and AE-QoL) will also be assessed.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.6.1-9"></a>

###### Exploratory endpoint instruments

> “AECT: Angioedema Control Test, AE-QoL: Angioedema Quality of Life”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.1.6.1-10"></a>

###### Validation of outcomes instruments: AECT scoring and cut-off

> “The AECT comes with high levels of internal consistency and test-retest-reliability and a cut-off value of 10 points to distinguish patients with poorly controlled and well controlled HAE.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-3.1.1.6.1-11"></a>

###### Validation of outcomes instruments: AECT development

> “A 4-item AECT with recall periods of 4 weeks and 3 months was developed based on 106 potential items tested in 97 patients with mast cell mediator-induced (n = 49) or bradykinin-mediated recurrent AE (n = 48).”
> “Its validity and reliability need to be determined in future independent studies.”

Source: [Weller et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31815297/)

<a id="topic-3.1.1.6.1-12"></a>

###### Validation of outcomes instruments: AE-QoL minimal clinically important difference

> “The MCID of the AE-QoL total score was found to be six points.”

Source: [Weller et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27038109/)

<a id="topic-3.1.1.6.1-13"></a>

###### Validation of outcomes instruments: AE-QoL content validation and psychometric evaluation

> “Patients agreed that the questionnaire items and response options were clear and relevant, and the 4-week recall period was appropriate.”

Source: [Vanya et al. (2023)](https://link.springer.com/article/10.1186/s41687-023-00576-w)

<a id="topic-3.1.1.6.1-14"></a>

###### Validation of outcomes instruments: AE-QoL content validation in adults and adolescents

> “Adolescents also reported that questions about school-related impacts were missing and would be important to ask about specifically.”

Source: [Broderick et al. (2025)](https://link.springer.com/article/10.1186/s41687-025-00876-3)

<a id="topic-3.1.1.6.1-15"></a>

###### Validation of outcomes instruments: AE-QoL psychometric validation

> “The AE-QoL demonstrated strong reliability, validity, and ability to detect change”

Source: [Feld et al. (2026)](https://link.springer.com/article/10.1186/s41687-026-01128-8)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Registry planned enrollment

> “Enrollment (Estimated) 90”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned participants per treatment group

| Treatment group | Planned participants |
| --- | --- |
| “ADX-324 300 mg Q6M (1.5ml)” | “n=30” |
| “ADX-324 240 mg Q3M (1.2ml)” | “n=30” |
| Placebo | “Placebo (1.2 ml) n=15 or (1.5 ml) n=15” |

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-3.1.1.7.1-3"></a>

###### Participants analyzed

No evidence found.

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Primary comparison and superiority criterion

> “The analysis that will affirm this objective is the comparison of the time-normalized number of investigator-confirmed HAE attacks (per month) from Day 22 to Week 25 visit in patients dosed with onvuzosiran at 300 mg Q6M with those dosed with placebo (PBO).”
> “A statistically significant reduction in attack rate will demonstrate the statistical superiority of onvuzosiran.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.7.2-2"></a>

###### Analysis populations

No evidence found.

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

No results are available. The trial began in August 2025, enrollment is ongoing, and the estimated primary completion date is November 2027, with topline data expected by the end of 2027. Planned enrollment is approximately 90 participants: 30 per onvuzosiran group and 30 receiving placebo, divided into two injection volumes of 15 participants each. This sample size limits the precision of safety estimates and of any subgroup analysis. The primary endpoint compares only the 300 mg every-6-months group with placebo; the 240 mg every-3-months comparison is a secondary endpoint. The controlled period lasts 25 weeks, so participants in the every-6-months group receive one active dose and the controlled data do not cover a second 6-month dosing interval. Attacks before Day 22 are excluded from the primary analysis, so the primary endpoint does not describe protection during the first 3 weeks after the first dose. The comparator is placebo, so the trial does not provide a direct comparison with an approved long-term prophylactic agent. Eligibility is limited to adults with type I or type II HAE who have at least 1 investigator-confirmed attack in the first 4 weeks of screening or at least 2 in 8 weeks, who complete washout of long-term prophylaxis, and who are judged able to use on-demand treatment alone; HAE with normal C1 inhibitor, clinically significant renal or hepatic disease, and prior RNA- or DNA-based HAE therapy are excluded. The doses were selected from pharmacodynamic data in healthy volunteers and from the attack-free intervals of 3 participants with HAE whose phase 2a doses were lower or less frequent than the phase 3 regimens. The design is described only in the registry record, ethics summaries, and sponsor documents; no peer-reviewed protocol publication was identified.

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213); [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm); [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf); [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf); [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/stop-hae-a-phase-3-study-of-adx-324-in-hae/); [Santé.fr (2026)](https://www.sante.fr/essais-cliniques/2025-521352-38-00/stop-hae-etude-de-phase-iii-randomisee-en-double-aveugle-et-controlee-par-placebo-evaluant-l-action-de-l-adx-324-un-sirna-ciblant-la-prekallikreine-chez-des-participants-atteints-d-angio-oedeme-hereditaire); [ADARx Pharmaceuticals](https://stophae.com/)

<a id="heading-3.1.2"></a>

#### 3.1.2 ADX-324-101

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Registry objective: Part A and Part B

> “The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-324 in healthy volunteers (HV) and in patients with Hereditary Angioedema (HAE).”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.1-2"></a>

###### Part A: primary objective at first dosing

> “The primary objective of the study is to evaluate the safety and tolerability of ADX-324 when administered by subcutaneous injection.”

Source: [ADARx Pharmaceuticals (2023)](https://www.adarx.com/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324/)

<a id="topic-3.1.2.1-3"></a>

###### Part A and Part B: objectives in the quarterly report

> “Our Phase 1/2 clinical trial evaluated the safety and tolerability, PK activity and PD activity of onvuzosiran in healthy volunteers and HAE patients.”

Source: [ADARx Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458444/adrx-20260930.htm)

<a id="topic-3.1.2.1-4"></a>

###### Part B: secondary objective and exploratory efficacy endpoints

> “The Phase 2a portion evaluated the safety and tolerability, pharmacokinetic (PK) activity and pharmacodynamic (PD) activity of onvuzosiran in HAE patients.”
> “with a secondary objective of PK activity and PD activity.”
> “Exploratory endpoints also included several measures of efficacy, including among other things, the reduction in the rate of HAE attacks, HAE attacks requiring treatment and HAE quality of life.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Registry site, dates, and status

| Field | Reported value |
| --- | --- |
| Location | “Adelaide, South Australia, Australia, 5000 CMAX Clinical Research” |
| Study start | “Study Start (Actual) 2022-12-14” |
| Primary completion | “Primary Completion (Estimated) 2027-12-31” |
| Study completion | “Study Completion (Estimated) 2027-12-31” |
| Status | “Active, not recruiting” |

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.2-2"></a>

###### Part A: country at first dosing

> “The study is being conducted in Australia”

Source: [ADARx Pharmaceuticals (2023)](https://www.adarx.com/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324/)

<a id="topic-3.1.2.2-3"></a>

###### Part B: start date

> “In January 2024, we initiated our Phase 2a clinical trial of SC doses of onvuzosiran in patients with HAE.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.2-4"></a>

###### Part A interim analysis: follow-up at the time of analysis

> “The interim analysis from blinded data includes observations up to 155 days post-dose; participants will be observed up to 12 months.”

Source: [Smith et al. (2023)](https://www.annallergy.org/article/S1081-1206%2823%2900702-0/fulltext)

<a id="topic-3.1.2.2-5"></a>

###### Part A and Part B: data cutoff of the workshop abstract

> “Results are shared here from data-cut as of December 5th, 2024.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.2-6"></a>

###### Part A and Part B: data dates of the AAAAI poster figures

> “Draft data as of Dec 4, 2024”
> “Draft data as of April 2025”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.2.2-7"></a>

###### Part B: safety and efficacy data cutoffs in the prospectus

> “Onvuzosiran has been generally well-tolerated in both healthy volunteers and in HAE patients as of the August 5, 2026 safety data cutoff date, with no treatment-related SAEs.”
> “with one patient remaining attack-free for 18 consecutive months on Q6M dosing as of the August 19, 2026 data cutoff date, after one mild attack on Day 153.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.2-8"></a>

###### Part B: data cutoff of the November 2026 presentation

> “Interim data as of the November 5, 2026 cutoff date”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Registry official title

> “A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study in Healthy Volunteers and a Phase 2a, Open-Label Study in Patients With Hereditary Angioedema to Evaluate the Safety, Tolerability, PK and PD of ADX-324”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.3-2"></a>

###### Registry design: two parts

> “The clinical study described in this protocol is a Phase 1, single-center study evaluating safety, tolerability, PK, and PD of ADX-324.”
> “Randomized, double-blind, placebo-controlled, parallel group, single ascending dose (SAD) in HV with up to 6 dose cohorts.”
> “Expansion cohort in participants with Hereditary Angioedema (HAE) at selected dose from Part A and will be open label.”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.3-3"></a>

###### Part A: randomization ratio and sentinel dosing

> “For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-324): 2 participants to control (matched placebo).”
> “Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed.”
> “The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.3-4"></a>

###### Part A: cohorts as described in the prospectus

> “We conducted a Phase 1, randomized, placebo-controlled, double-blind clinical trial in healthy volunteers, where participants were administered single ascending, SC doses of onvuzosiran, ranging from 0.4 to 6 mg/kg across seven cohorts.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.3-5"></a>

###### Part A and Part B: cohorts as described in the workshop abstract

> “A Phase 1, healthy volunteer placebo-controlled single dose escalation study of ADX-324 in 6 cohorts (0.4 mg/kg to 6 mg/kg) and 1 cohort administered 2 doses of 140 mg ADX-324 or placebo 3 months apart, and an open-label Phase 2a study in HAE patients with ADX-324 administered SC every 6 months was conducted”
> “in a phase 2a, dose range finding study”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.3-6"></a>

###### Part A and Part B: cohorts as described in the EAACI abstract

> “A Phase 1, randomized, placebo-controlled, single–ascending-dose trial of subcutaneous (SC) onvuzosiran (0.4 mg/kg to 6 mg/kg) was conducted in healthy adults across 5 doses with an additional group of repeat-dosing every 3 months.”
> “An open-label Phase 2 study of 245 mg every 6 months in HAE patients is completing follow-up.”

Source: [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf)

<a id="topic-3.1.2.3-7"></a>

###### Part A interim: planned dose escalation and planned HAE study

> “A double-blind, first-in-human Phase 1 study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ADX-324 in healthy volunteers (HVs) following a single subcutaneous dose (NCT05691361).”
> “The study continues, dose-escalating ADX-324 for 2 mandatory (4 and 8 mg/kg) and one optional (up to 12 mg/kg) cohorts in HVs.”
> “An open-label, single-dose study in HAE patients is planned.”

Source: [Smith et al. (2023)](https://www.annallergy.org/article/S1081-1206%2823%2900702-0/fulltext)

<a id="topic-3.1.2.3-8"></a>

###### Part B: continued dosing after the objectives were assessed

> “While patients continue to be dosed, given the reduction in HAE attack rate observed as of the August 19, 2026 data cutoff date, we believe sufficient safety, PK data and PD data have been collected to assess the primary and secondary objectives.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Part A: inclusion criteria for healthy volunteers

> “Male and female adults 18 to 55 years old”
> “Body mass index (BMI) between 18 and 30 kg/m2”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.4-2"></a>

###### Part A: selected exclusion criteria for healthy volunteers

> “History of liver disease, Gilbert's syndrome, or abnormal liver function test”
> “Estimated creatinine clearance <60 mL/min or serum creatinine > 1.5-fold upper limit of normal.”
> “Use of any prescription, vaccines, supplements/vitamins, or over-the counter medication”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.4-3"></a>

###### Part B: inclusion criteria for participants with HAE

> “Male and female ≥18 years old, inclusive, at the time of signing the PICF”
> “Confirmed diagnosis of HAE Types I or II”
> “Evidence of an average of (at least) one HAE attack per month”
> “Participants must have access to, and the ability to use, acute medication(s) to treat angioedema attacks.”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.4-4"></a>

###### Part B: selected exclusion criteria for participants with HAE

> “Concurrent diagnosis of any other type of chronic angioedema”
> “History of clinically significant arterial or venous thrombosis, or current history of a clinically significant prothrombotic risk.”
> “Use of C1-INH products, androgens, antifibrinolytics or other small molecule medications for routine prophylaxis within four half-lives prior to screening”
> “Treatment with another investigational product or biologic agent within 30 days prior to the study drug administration”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Registry interventions

| Intervention | Description |
| --- | --- |
| ADX-324 | “siRNA duplex oligonucleotide” |
| Placebo | “saline” |

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.5-2"></a>

###### Part B: starting dose selection

> “This will be initiated at the dose level determined by the Safety Review Committee from SAD in HVs.”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.5-3"></a>

###### Part A: weight-based cohorts in the pharmacokinetic figure

| Cohort | Dose as printed |
| --- | --- |
| Phase 1 cohort 1 | “Phase 1 Cohort 1 (0.4 mg/mkg)” |
| Phase 1 cohort 2 | “Phase 1 Cohort 2 (1.0 mg/mkg)” |
| Phase 1 cohort 3 | “Phase 1 Cohort 3 (2.0 mg/mkg)” |
| Phase 1 cohort 4 | “Phase 1 Cohort 4 (4.0 mg/mkg)” |
| Phase 1 cohort 5 | “Phase 1 Cohort 5 (6.0 mg/mkg)” |
| Phase 2 cohort 1 | “Phase 2 Cohort 1 (2.0 mg/mkg)” |

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.2.5-4"></a>

###### Part A: repeat-dose cohort

> “one cohort received two 140 mg doses 3 months apart”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.2.5-5"></a>

###### Part B: doses and dosing interval

> “Phase 2a doses: 122.5 mg Q6M, or 245 mg Q6M”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.5-6"></a>

###### Part B: doses as stated in the AAAAI abstract

> “An ongoing open-label Phase 2 study in HAE patients involves SC ADX-324 dosing Q6M.”
> “In Phase 2, one patient received 122.5 mg and two patients received 245 mg.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

<a id="topic-3.1.2.5-7"></a>

###### Part B: doses as stated in the workshop abstract

> “Three HAE patients have been dosed with ADX-324 at 2 mg/kg (n = 1, approximately 125 mg) and 245 mg (n = 2).”
> “one HAE patient was dosed at 122 mg and two patients were dosed at 245 mg.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.5-8"></a>

###### Part B: doses as stated in the EAACI poster

> “Open-label Phase 2 study of 245 mg or 122 mg every 6 months in HAE patients is completing follow-up”

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-3.1.2.5-9"></a>

###### Part B: doses compared with the phase 3 regimens

> “Phase 2a: Dosed at Q6M, all were doses either significantly lower than in Phase 3 or less frequent (Phase 3 dose cohorts: 300 mg Q6M or 240 mg Q3M)”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Adverse Event Incidence as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Registry primary outcome measures

> “To evaluate the safety and tolerability of ADX-324 in HVs by incidence, relationship, and severity of adverse events and serious adverse events”
> “To evaluate the safety and tolerability of ADX-324 in HVs by change in baseline electrocardiogram (ECG) parameters (PR, QRS, QT, and QTcF intervals)”
> “To evaluate the safety and tolerability of ADX-324 in HAE by incidence, relationship, and severity of adverse events and serious adverse events”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.6.1-2"></a>

###### Registry secondary outcome measures: prekallikrein and kallikrein

> “To characterize the PD of ADX-324 in HVs by the Change from base in plasma concentrations over time of pre Kallikrein (PKK)”
> “To characterize the PD of ADX-324 in HVs by the Change from base in plasma concentrations over time of Kallikrein (KK)”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.6.1-3"></a>

###### Part B: prekallikrein-kallikrein reduction as a predictor of attacks

> “The patients’ data also supports that PKK-KK response can be used to predict HAE attacks and PKK-KK reductions > 70% are likely to prevent HAE attacks.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.6.1-4"></a>

###### Part B: suppression threshold proposed for an attack-free state

> “We also correlated the episodes of attack with the PKK levels and found that no attacks occurred when the PKK suppression was >80%, suggesting that >80% suppression is potentially needed to achieve a maximal attack-free state.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.6.1-5"></a>

###### Same target: prekallikrein concentration and attack rate with donidalorsen

> “These reductions in HAE attack rates were associated with corresponding reductions in mean plasma prekallikrein trough concentrations of 73% in the donidalorsen Q4W group and 47% in the donidalorsen Q8W group.”
> “Reductions in predicted prekallikrein concentrations were correlated with reductions in predicted HAE attack rates”

Source: [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12597964/)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Registry planned enrollment

> “Enrollment (Estimated) 53”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.7.1-2"></a>

###### Part A: participants in the prospectus

> “Thirty-eight of 49 healthy volunteers were administered onvuzosiran and the remaining 11 received placebo.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.7.1-3"></a>

###### Part A: participants in the AAAAI poster

> “38 dosed, 11 placebo (total 49)”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.2.7.1-4"></a>

###### Part A and Part B: participants in the February 2026 release

> “The Phase 1 placebo-controlled single-dose escalation study was conducted in 43 healthy participants who received onvuzosiran (n=32) in 5 cohorts from 0.4 mg/kg to 6 mg/kg or placebo (n=11)”
> “The open-label Phase 2a part of the study is evaluating plasma kallikrein levels and safety with subcutaneous dosing of onvuzosiran every six months in patients with HAE (n=3).”

Source: [ADARx Pharmaceuticals onvuzosiran data announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-presents-onvuzosiran-data-supporting-potential-for-sustained-attack-free-rates-with-reduced-treatment-burden-in-patients-with-hae/)

<a id="topic-3.1.2.7.1-5"></a>

###### Part A interim: participants per cohort

> “Four dose cohorts are assessed to date. In each cohort, 6 participants received ADX-324, and 2 received placebo.”

Source: [Smith et al. (2023)](https://www.annallergy.org/article/S1081-1206%2823%2900702-0/fulltext)

<a id="topic-3.1.2.7.1-6"></a>

###### Part A: participants by total dose group in the pharmacodynamic figure

| Total dose group | Group as printed |
| --- | --- |
| Placebo | “ph1, 0 mg (n=11)” |
| Above 0 to 100 mg | “ph1, >0-100 mg (n=13)” |
| Above 100 to 200 mg | “ph1, >100-200 mg (n=8)” |
| Above 200 to 250 mg | “ph1, >200-250 mg (n=6)” |
| Above 250 to 300 mg | “ph1, >250-300 mg (n=3)” |
| Above 300 to 350 mg | “ph1, >300-350 mg (n=4)” |
| Above 350 mg | “ph1, >350 mg (n=4)” |
| 300 mg plus or minus 25 mg | “ADX-324 300 mg +/- 25 mg (n=5)” |

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.2.7.1-7"></a>

###### Part B: participants enrolled

> “The clinical trial enrolled three patients.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Part A: analysis by total fixed dose

> “When analyzed by total fixed dose, we observed in healthy volunteers that following a single 300 mg +/- 25 mg achieved comparable performance”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.7.2-2"></a>

###### Part A: summary statistic for prekallikrein-kallikrein reduction

> “A single SC injection of ADX-324 of 300 mg (± 25 mg) achieved a mean (SEM) PKK-KK reduction from baseline of > 90% at nadir”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.7.2-3"></a>

###### Part A and Part B: duration of assessments

> “PKK levels and safety assessments were performed for up to 1 year in Phase 1 and are ongoing in Phase 2a.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.7.2-4"></a>

###### Part B: longest follow-up in the AAAAI abstract

> “Plasma PKK-KK protein levels and safety were assessed through Day 445, the longest follow-up.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

<a id="topic-3.1.2.7.2-5"></a>

###### Part B: attack-free interval measured from approximate full inhibition

> “One known feature of siRNA therapeutic candidates such as onvuzosiran is lag time of about 22 days between initial treatment and full inhibition.”
> “The first dotted vertical line (green) indicates the approximate time of full inhibition, while the second dotted vertical line represents 3 months after the first dose.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Registry recruitment status and results posting

> “Active, not recruiting No longer looking for participants”
> “No Results Posted”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.8.1-2"></a>

###### Part A: completion and withdrawals

> “In the completed Phase 1 portion of our ongoing Phase 1/2 clinical trial”
> “Onvuzosiran was generally well-tolerated and no participants experienced serious adverse events or adverse events that led to study withdrawal.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.1-3"></a>

###### Part B: participants followed and one withdrawal

> “Two patients are still being followed, and one patient withdrew due to administrative reasons.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.1-4"></a>

###### Part A and Part B: discontinuations due to adverse events

> “There was no discontinuations of therapy due to drugs effects.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

> “No related SAEs or withdrawal due to AEs were reported.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Part A interim: prekallikrein nadir by weight-based dose

> “Mean nadir PKK levels were 39% (n=6), 14% (n=6), and 20% (n=5) of baseline following single doses of 0.4, 1.0, and 2.0 mg/kg, respectively.”
> “Cohort 2 PKK mean level remains 21% 99 days post-dose.”

Source: [Smith et al. (2023)](https://www.annallergy.org/article/S1081-1206%2823%2900702-0/fulltext)

<a id="topic-3.1.2.8.3-2"></a>

###### Part A: dose dependence of prekallikrein-kallikrein reduction

> “In the placebo-controlled single dose escalation study of ADX-324, a strong dose-dependent PKK-KK reduction was observed.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.8.3-3"></a>

###### Part A: 6 mg/kg cohort, reduction at nadir and at 6 months

> “In the completed Phase 1 portion of our ongoing Phase 1/2 clinical trial, we observed at the 6 mg/kg dose level that a single injection reduced circulating PKK/KK levels by a mean of 94% (88% to 97%, median 96%) at nadir and maintained 84% mean suppression (78% to 92%, median 82%) at 6 months.”
> “Three of the four participants at this dose level reached below LLOQ for PKK/KK levels at nadir.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.3-4"></a>

###### Part A: 300 mg plus or minus 25 mg, reduction at nadir and at Day 169 in the prospectus

> “exceeding 90% mean reduction (84% to 96%, median 95%) at nadir with at least 80% mean suppression (65% to 90%, median 83%) sustained through the six-month timepoint (Day 169, as defined in our Phase 3 STOP-HAE trial)”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.3-5"></a>

###### Part A: 6 mg/kg cohort in the November 2026 presentation

> “At the 6 mg/kg dose level, we observed that a single SC injection reduced circulating PKK/KK levels by a mean of 94% at nadir and maintained 84% mean suppression at 6 months”
> “Three of the four participants reached below LLOQ”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="topic-3.1.2.8.3-6"></a>

###### Part A: 300 mg figures as attributed in the November 2026 presentation

> “Phase 1 support: 94% mean (88-97%) reduction at nadir, 84% mean (78-92%) reduction at 6mo at 300 mg +/-25 mg Q6M”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="topic-3.1.2.8.3-7"></a>

###### Part A: 300 mg plus or minus 25 mg in the AAAAI poster

> “In Phase 1, a single SC injection of ADX-324 at 300 mg (±25 mg) achieved a mean PKK-KK reduction from baseline of over 90% at nadir, with >80% reduction maintained through Day 169.”
> “In HV, the 300 mg dose, not a lower one, achieved a 93% mean PKK-KK reduction at nadir and an 80% mean reduction at 6 month”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.2.8.3-8"></a>

###### Part A: 300 mg dose in the February 2026 release

> “The 300 mg dose showed a 93% reduction at the lowest point, with 80% reduction maintained through Day 169.”

Source: [ADARx Pharmaceuticals onvuzosiran data announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-presents-onvuzosiran-data-supporting-potential-for-sustained-attack-free-rates-with-reduced-treatment-burden-in-patients-with-hae/)

<a id="topic-3.1.2.8.3-9"></a>

###### Part A: 300 mg plus or minus 25 mg in the workshop abstract

> “A single SC injection of ADX-324 of 300 mg (± 25 mg) achieved a mean (SEM) PKK-KK reduction from baseline of > 90% at nadir, and > 80% reduction % maintained out to Day 169 (Week 25)”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.8.3-10"></a>

###### Part A: 300 mg dose in the EAACI abstract

> “In Phase 1, a single SC dose of 300 mg reduced plasma kallikrein levels to over 90% at nadir, with maintenance of 80% reduction through Week 25.”

Source: [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf)

<a id="topic-3.1.2.8.3-11"></a>

###### Part A: 300 mg dose in the ACAAI abstract

> “In Phase I, a single SC dose of 300 mg reduced plasma kallikrein levels to over 90% at nadir, with maintenance of 80% reduction through Week 25.”

Source: [Riedl et al. (2026b)](https://www.annallergy.org/article/S1081-1206%2826%2900563-6/fulltext)

<a id="topic-3.1.2.8.3-12"></a>

###### Part B: prekallikrein-kallikrein reduction compared with healthy volunteers at similar doses

> “Their PKK-KK reductions mirrored those observed in healthy subjects dosed with ADX-324 at similar levels, supporting the Phase 3 target >80% PKK-KK reduction throughout 6 months in HAE patients at the 300 mg dose.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

> “HAE (122.5 mg, n=1)”
> “HV (122.5 mg +/- 20 mg, n=7)”
> “% PKK-KK reduction from baseline in HV and HAE patients were similar at similar doses.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

> “The PD results showed similar PKK inhibition between healthy volunteers in the Phase 1 clinical trial and HAE patients.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.3-13"></a>

###### Part B: attack-free period after the first dose, August 2026 cutoff

> “Despite dosing at levels below or less frequent than those utilized in our ongoing Phase 3 STOP-HAE clinical trial”
> “all participants in the Phase 2a cohort remained attack-free for 3 months following the initial dose, with one patient remaining attack-free for 18 consecutive months on Q6M dosing as of the August 19, 2026 cutoff date, after one mild attack on Day 153.”
> “During the follow-up, with repeated treatments, the attack-free interval appears to extend over time.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.3-14"></a>

###### Part B: attack-free period after the first dose, November 2026 cutoff

> “All three patients (3/3) were attack-free for 3 months after the initial dose”
> “Patient 202 (245mg, Q6M) remained attack-free for a consecutive 21 months after one mild attack at Day 153”
> “Observed 100% Q3M attack-free rate in Phase 2a after the first dose”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="topic-3.1.2.8.3-15"></a>

###### Part B: attacks in relation to prekallikrein-kallikrein reduction

> “No attacks observed when PKK & KK reduction >80%”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

> “Notably, Phase 2 patients with >80% PKK-KK reductions experienced no HAE attacks, further supporting the potential of 300 mg Q6M to improve attack-free rates.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

> “Notably, HAE patients experienced no attacks when kallikrein levels were reduced by 80%, further supporting the potential of twice-yearly dosing to achieve high attack-free rates.”

Source: [ADARx Pharmaceuticals onvuzosiran data announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-presents-onvuzosiran-data-supporting-potential-for-sustained-attack-free-rates-with-reduced-treatment-burden-in-patients-with-hae/)

> “Notably, patients who had plasma kallikrein reduction of >80% were attack-free, supporting 300 mg Q6M dosing.”

Source: [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf)

> “Notably, patients who had plasma kallikrein reduction of >80% were attack-free, supporting 300 mg Q6M dosing.”

Source: [Riedl et al. (2026b)](https://www.annallergy.org/article/S1081-1206%2826%2900563-6/fulltext)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Part A interim: severity and most frequent adverse event

> “ADX-324 was safe and well tolerated; no serious adverse events (SAEs) were reported.”
> “All study drug-related AEs were mild except one moderate.”
> “The most frequent AE was headache.”

Source: [Smith et al. (2023)](https://www.annallergy.org/article/S1081-1206%2823%2900702-0/fulltext)

<a id="topic-3.1.2.8.5-2"></a>

###### Part A: most common adverse events and laboratory changes

> “The most common adverse events observed in participants dosed with onvuzosiran included injection site reactions, headache, laboratory changes in blood creatinine phosphokinase (CK) and increases in liver function test (ALT/AST).”
> “All cases of laboratory changes were asymptomatic, transient, and resolved without treatment within a short period of time.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.5-3"></a>

###### Part A: headache and injection-site reaction frequency

> “ADX-324 was well-tolerated with headache and injection-site reaction being the most common AEs in Phase 1 portion (28.9%).”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.8.5-4"></a>

###### Part A: serious adverse events by dose in the November 2026 presentation

> “Well-tolerated with doses up to 6.0 mg/kg, no treatment-related SAEs”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="topic-3.1.2.8.5-5"></a>

###### Part B: safety through the August 2026 cutoff

> “Onvuzosiran has been generally well-tolerated, consistent with the safety results observed in Phase 1, with no treatment-related SAEs reported in subjects dosed with onvuzosiran as of the August 5, 2026 safety data cutoff date.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.5-6"></a>

###### Part B: safety through the November 2026 cutoff

> “Generally well-tolerated, consistent with the safety results observed in Phase 1, with no SAEs reported in participants dosed with onvuzosiran”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="topic-3.1.2.8.5-7"></a>

###### Part A and Part B: serious adverse events and repeat dosing in the AAAAI poster

> “No Serious Adverse Events (SAE’s) were reported in 38 healthy volunteer phase 1 participants and 3 phase 2 HAE patients.”
> “Repeat dosing at 6-month intervals in phase 2 HAE patients was not associated with any safety signal.”
> “Ph1 study showed no drug-related serious adverse events”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.2.8.5-8"></a>

###### Part A and Part B: serious adverse events in the EAACI poster

> “In 49 healthy volunteer phase 1 participants and 3 phase 2 HAE patients, no Serious Adverse Events (SAEs) were reported in patients treated with onvuzosiran”

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-3.1.2.8.5-9"></a>

###### Part A and Part B: tolerability in the February 2026 release

> “In the Phase 1/2 study, onvuzosiran was well tolerated, and no serious adverse events were reported, nor were there any treatment-related discontinuations.”

Source: [ADARx Pharmaceuticals onvuzosiran data announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-presents-onvuzosiran-data-supporting-potential-for-sustained-attack-free-rates-with-reduced-treatment-burden-in-patients-with-hae/)

<a id="topic-3.1.2.8.5-10"></a>

###### Part A and Part B: tolerability in the congress abstracts

> “ADX-324 was well tolerated in Phase 1 and 2.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

> “Phase 1 and 2 studies showed the drug to be well-tolerated.”

Source: [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf)

> “Phase 1 and 2 studies showed onvuzosiran to be well-tolerated.”

Source: [Riedl et al. (2026b)](https://www.annallergy.org/article/S1081-1206%2826%2900563-6/fulltext)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

Part A enrolled healthy volunteers aged 18 to 55 years with a body mass index of 18 to 30 kg/m2, so its pharmacodynamic and safety findings come from a population without HAE. Its dose groups were small: the AAAAI poster lists 3 to 13 participants per total dose group, 5 participants in the 300 mg plus or minus 25 mg group, and the prospectus reports the 6 mg/kg results for 4 participants, 3 of whom were below LLOQ at nadir.

Part B was open-label and uncontrolled and enrolled 3 participants, one of whom withdrew for administrative reasons. Its doses (122.5 mg or 245 mg every 6 months) differ from the phase 3 regimens of 300 mg every 6 months and 240 mg every 3 months. All phase 2a dosing was every 6 months, and the November 2026 presentation describes the 3-month attack-free result as an “Observed 100% Q3M attack-free rate in Phase 2a after the first dose”.

No baseline characteristics, baseline attack rates, on-treatment attack rates, or quality-of-life results were identified. Efficacy is reported as attack-free intervals of individual participants and as an association between attacks and the degree of prekallikrein-kallikrein reduction, and the prospectus figure marks the approximate time of full inhibition (about Day 22) and the point 3 months after the first dose. The proposed threshold differs between documents: “> 70%” in the workshop abstract and “>80%” in the prospectus and other sponsor documents.

The results are available only in congress abstracts, posters, press releases, a corporate presentation, and SEC filings. No peer-reviewed full article was identified, the registry record shows “No Results Posted”, and primary completion is estimated for 2027-12-31. The documents use data cutoffs from December 2024 to November 2026.

The documents report different numbers for Part A: 43 participants (32 onvuzosiran, 11 placebo) in 5 cohorts in the February 2026 release; 49 participants (38 onvuzosiran, 11 placebo) in the posters and the prospectus; and 5, 6, or 7 cohorts in different documents. The prospectus attributes the 94% nadir and 84% six-month reductions to the 6 mg/kg cohort, while the November 2026 presentation attributes them to 6 mg/kg on one page and to 300 mg plus or minus 25 mg on another. The first Part B dose is written as 122 mg, 122.5 mg, or approximately 125 mg.

Safety reporting gives one frequency, 28.9%, attached to headache and injection-site reaction in Part A, and no counts for creatine phosphokinase changes or liver enzyme increases. Serious adverse events are described variously as absent, absent when treatment-related, or absent when drug-related. No immunogenicity data and no electrocardiogram results were identified, although electrocardiogram change is a registry primary outcome.

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361); [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm); [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0); [ADARx Pharmaceuticals onvuzosiran data announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-presents-onvuzosiran-data-supporting-potential-for-sustained-attack-free-rates-with-reduced-treatment-burden-in-patients-with-hae/); [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf); [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095); [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/); [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf); [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-3.1.2.9-2"></a>

###### Interim and early-phase results: sponsor statement

> “The results from clinical trials or preclinical studies of a therapeutic candidate may not predict the results of later clinical trials of the therapeutic candidate, and interim, topline, or preliminary results of a clinical trial are not necessarily indicative of final results.”

Source: [ADARx Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458444/adrx-20260930.htm)

<a id="heading-3.1.3"></a>

#### 3.1.3 ADX-324-302

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Registry brief summary

> “Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial.”
> “The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE).”
> “The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Registry dates and number of locations

> “Study Start (Actual) 2026-04-02 Primary Completion (Estimated) 2030-06-30 Study Completion (Estimated) 2030-06-30”
> “This study has 48 locations”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-3.1.3.2-2"></a>

###### UK research ethics committee opinion

| Field | Reported value |
| --- | --- |
| REC reference | “26/SC/0102” |
| Date of REC opinion | “12 May 2026” |
| REC opinion | “Further Information Favourable Opinion” |

Source: [Health Research Authority (2026)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/extension-study-of-adx-324-in-hae/)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Registry design details

| Field | Reported value |
| --- | --- |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Double” |

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-3.1.3.3-2"></a>

###### Treatment duration and maintenance of the core-study blind

> “All eligible participants in the main study will be enrolled on the extension study and administered ADX-324 for up to 3 years.”
> “In order to maintain the blind in the core study, all participants will receive an injection Q3M; participants in the Q6M regimen will alternate between ADX-324 and placebo Q3M while participants in the Q3M group will receive ADX-324 Q3M as outlined.”

Source: [Health Research Authority (2026)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/extension-study-of-adx-324-in-hae/)

<a id="topic-3.1.3.3-3"></a>

###### Sponsor description of the extension

> “A long-term extension clinical trial will further evaluate open-label onvuzosiran treatment for up to three years, with, after 6 months, all participants (including placebo patients from STOP-HAE) moved onto active drug in the open label long term follow up.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.3.3-4"></a>

###### Attack recording during the extension

> “The eDiary will be used to continue to track your HAE attacks throughout the extension study.”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Registry inclusion and exclusion criteria

> “Have a documented diagnosis of HAE (Type I or II)”
> “Completed Study ADX-324-301”
> “Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)”
> “A negative reaction to study drug in ADX-324-301”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-3.1.3.4-2"></a>

###### Eligibility assessment at the end of the core study

> “participants will be assessed for study eligibility for this extension study.”

Source: [Health Research Authority (2026)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/extension-study-of-adx-324-in-hae/)

<a id="topic-3.1.3.4-3"></a>

###### Early withdrawal from the core study

> “Should you end participation early in the primary study, you will not be eligible to participate in the extension study.”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Regimens by core-study assignment

> “Participants who received ADX-324 in the core study will continue to receive the same dosing regimen as in the core study (ie, ADX-324 300 mg every 6 months [Q6M] in Group 1 or 240 mg every 3 months [Q3M] in Group 2).”
> “Participants who received placebo 1.5 mL in the core study will receive ADX-324 300 mg Q6M (Group 1) and those who received placebo 1.2 mL in the core study will receive 240 mg Q3M (Group 2).”

Source: [Health Research Authority (2026)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/extension-study-of-adx-324-in-hae/)

<a id="topic-3.1.3.5-2"></a>

###### Registry interventions

| Intervention | Reported description |
| --- | --- |
| ADX-324 Dose Level 1 | “siRNA duplex oligonucleotide” |
| ADX-324 Dose Level 2 | “siRNA duplex oligonucleotide” |

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-3.1.3.5-3"></a>

###### Study drug cost to participants

> “All participants will receive ADX-324 at no cost.”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary endpoint: registry definition

> “Incidence and severity of treatment-emergent adverse events”
> “Month 36”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-3.1.3.6.1-2"></a>

###### Secondary endpoint: registry definition

> “Number of Investigator-confirmed HAE attacks per month”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Registry planned enrollment

> “Enrollment (Estimated) 90”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-3.1.3.7.1-2"></a>

###### Participants analyzed

No evidence found.

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

No evidence found.

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

No results are available. The extension began in April 2026 and has an estimated primary completion date of June 2030. Allocation is non-randomized and every participant receives onvuzosiran, so the extension has no concurrent control group for safety or attack-rate comparisons. The core-study assignment remains masked through alternating onvuzosiran and placebo injections in the every-6-months group; the extension itself is not blinded to active treatment. Enrollment is limited to participants who completed STOP-HAE, and participants with a negative reaction to study drug in STOP-HAE are excluded, so the extension population may under-represent participants who did not tolerate or did not continue onvuzosiran. The primary endpoint is the incidence and severity of treatment-emergent adverse events through Month 36, and the monthly attack rate is a secondary endpoint. Planned enrollment is approximately 90 participants, which limits the detection of uncommon adverse events. No statistical analysis plan or analysis population definitions have been published.

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499); [Health Research Authority (2026)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/extension-study-of-adx-324-in-hae/); [ADARx Pharmaceuticals](https://stophae.com/)

<a id="heading-3.1.4"></a>

#### 3.1.4 OASIS-HAE

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Prophylaxis objective

> “prophylaxis to prevent attacks”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Registry study dates

> “Study Start (Actual) 2021-12-03”
> “Primary Completion (Actual) 2023-11-09”
> “Study Completion (Actual) 2023-11-09”

Source: [ClinicalTrials.gov NCT05139810](https://clinicaltrials.gov/study/NCT05139810)

<a id="topic-3.1.4.2-2"></a>

###### Registered study locations and countries

> “This study has 51 locations”

Source: [ClinicalTrials.gov NCT05139810](https://clinicaltrials.gov/study/NCT05139810)

| Field | Reported value |
| --- | --- |
| Country | “Belgium” |
| Country | “Bulgaria” |
| Country | “Canada” |
| Country | “Denmark” |
| Country | “France” |
| Country | “Germany” |
| Country | “Israel” |
| Country | “Italy” |
| Country | “Netherlands” |
| Country | “Poland” |
| Country | “Spain” |
| Country | “Turkey (Türkiye)” |
| Country | “United Kingdom” |
| Country | “United States” |

Source: [ClinicalTrials.gov NCT05139810](https://clinicaltrials.gov/study/NCT05139810)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Phase 3 design

> “double-blind, randomized”

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Age eligibility

> “12 years of age and older”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Dose, route, and dosing intervals

> “80 mg subcutaneously”
> “once every 4 or 8 weeks.”

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using HAE Attack Rate per Four Weeks as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Primary clinical endpoint: attack rate over the 24-week treatment period

> “HAE attacks per 4 weeks”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Planned enrollment

| Population | Participants |
| --- | --- |
| Planned total | “84” |

Source: [Ionis Pharmaceuticals protocol and statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf)

<a id="topic-3.1.4.7.1-2"></a>

###### Actual treated populations

| Population | Participants |
| --- | --- |
| Donidalorsen every four weeks | “45” |
| Donidalorsen every eight weeks | “23” |
| Placebo | “22” |

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Full analysis set

> “all randomized patients who received at least 1 dose of Study Drug”

Source: [Ionis Pharmaceuticals protocol and statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf)

<a id="topic-3.1.4.7.2-2"></a>

###### Primary count-data model

> “Poisson regression model and Pearson chi-square scaling of standard errors”

Source: [Ionis Pharmaceuticals protocol and statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Treatment exposure

| Population | Participants |
| --- | --- |
| Treated | “90” |

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Baseline demographics

| Characteristic | Reported value |
| --- | --- |
| Mean age, years (SD) | “37 (14)” |
| Female, n (%) | “48 (53)” |

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Mean attack rate per four weeks: weeks 1–25 in the publication

| Treatment | Attack rate |
| --- | --- |
| Donidalorsen every four weeks | “0.44” |
| Donidalorsen every eight weeks | “1.02” |
| Placebo | “2.26” |

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

###### AE-QoL improvement relative to placebo at week 25: every-four-week regimen

> “18.6 points (95% CI, 9.5 to 27.7)”

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="topic-3.1.4.8.4-2"></a>

###### Exploratory and post hoc analysis status

> “All new analyses reported here are exploratory or post hoc, and resulting p‐values are nominal and not corrected for multiplicity.”

Source: [Riedl et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368753/)

<a id="topic-3.1.4.8.4-3"></a>

###### AE-QoL total score: clinically meaningful improvement at week 24

> “A greater proportion of the donidalorsen Q4W group achieved clinically meaningful improvement in AE‐QoL total score (≥ 6 points) vs. the placebo group (88.1% vs. 45.0%; odds ratio [OR], 12.2; 95% confidence interval [CI], 2.8 to 54.3; p < 0.001).”
> “Most Q8W patients (71.4%) also achieved the MCID, but while numerically larger, the difference between the donidalorsen Q8W and placebo groups was not statistically significant (OR, 3.5; 95% CI, 0.8 to 14.3; p = 0.087).”

Source: [Riedl et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368753/)

<a id="topic-3.1.4.8.4-4"></a>

###### AE-QoL domain scores from baseline to week 24

> “Patients reported decreases (improvements) in mean functioning domain scores from 45.2 at baseline to 8.0 at week 24 in the donidalorsen Q4W group and 51.2 to 18.2 in the donidalorsen Q8W group, compared with a decrease from 46.6 to 33.3 in the placebo group”
> “Mean fears/shame domain scores improved from 53.2 to 22.3, 54.8 to 27.1, and 57.0 to 51.6 in the donidalorsen Q4W, donidalorsen Q8W, and placebo groups, respectively.”
> “In the nutrition domain, patients reported improvements in means from 32.7 to 11.0 (Q4W), 36.9 to 17.6 (Q8W), and 36.4 to 28.5 (placebo).”
> “No significant differences in the change in the fatigue/mood domain were observed between the donidalorsen and placebo groups, but scores improved from 41.9 to 28.5 (Q4W), 39.5 to 31.4 (Q8W), and 34.1 to 30.3 (placebo).”

Source: [Riedl et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368753/)

<a id="topic-3.1.4.8.4-5"></a>

###### Angioedema Control Test: change from baseline and disease control at week 24

> “Least‐squares mean (LSM) changes from baseline to week 24 in AECT total score were statistically significantly larger in both the Q4W (7.2 points; 95% CI, 5.9 to 8.4) and Q8W donidalorsen (5.2 points; 95% CI, 3.4 to 7.0) groups than in the placebo group (1.2 points; 95% CI, −0.7 to 3.0; Q4W vs. placebo p < 0.001; Q8W vs. placebo p = 0.003).”
> “As reported previously, at week 24, 91% of patients in the donidalorsen Q4W group reported well‐controlled disease vs. 41% of patients in the placebo group”
> “a significantly greater proportion of patients in the donidalorsen Q8W group (74%) reported well‐controlled disease at week 24 compared with the placebo group (OR vs. placebo, 4.1; 95% CI, 1.2 to 14.4; p = 0.028).”
> “51% and 48% of patients in the donidalorsen Q4W and Q8W groups, respectively”
> “reported complete disease control (AECT = 16; Table 1).”

Source: [Riedl et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368753/)

<a id="topic-3.1.4.8.4-6"></a>

###### Patient Global Impression of Severity at week 24

> “82% of donidalorsen Q4W patients reporting improvement, that is, less severe disease at week 24 compared with baseline”
> “the 44% reporting improvements in disease severity in the placebo group (OR, 6.2; 95% CI, 1.4 to 28.2; p = 0.018; Figure 3).”

Source: [Riedl et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368753/)

<a id="topic-3.1.4.8.4-7"></a>

###### Work productivity and activity impairment at week 24

> “Mean presenteeism, the percent loss of productivity while at work/school, improved from 25.6% at baseline to 4.0% at week 24 in the donidalorsen Q4W group compared with a decrease from 30.7% to 19.8% in the placebo group”
> “Overall work/school impairment decreased from 28.4% to 4.7% in the donidalorsen Q4W group vs. 35.2% to 22.7% in the placebo group.”
> “Patients reported improvements in the overall activity impairment domain from 35.4% to 10.5% in the donidalorsen Q4W group vs. 34.7% to 21.2% in the placebo group.”
> “Numerical improvements from baseline to week 24 were observed in all WPAI domains in the donidalorsen Q8W group, but these changes did not reach significance vs. placebo”

Source: [Riedl et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368753/)

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Injection-site reactions

| Treatment | Participants, n (%) |
| --- | --- |
| Donidalorsen every four weeks, n=45 | “11 (24)” |
| Donidalorsen every eight weeks, n=23 | “1 (4)” |
| Placebo, n=22 | “1 (5)” |

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

The trial treated 90 participants: 45 received donidalorsen every 4 weeks, 23 received donidalorsen every 8 weeks, and 22 received placebo. The randomized comparison does not describe outcomes beyond Week 25. The full analysis set comprised “all randomized patients who received at least 1 dose of Study Drug”, and attack counts were analyzed with a “Poisson regression model and Pearson chi-square scaling of standard errors”. The placebo group of 22 participants and the every-8-week group of 23 participants limit precision for between-group estimates and for uncommon adverse events; injection-site reactions occurred in 11 of 45 participants (24%) receiving every-4-week dosing. Donidalorsen was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, baseline attack rates, observation periods, and attack-rate definitions (attacks per 4 weeks in this trial) can affect the reported rates.

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/); [Ionis Pharmaceuticals protocol and statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf); [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.5"></a>

#### 3.1.5 OASISplus

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Open-label extension cohort objective

> “The majority of patients enrolled in OASIS-HAE (83/90, 92.2%) rolled over into the open-label extension (OLE) cohort of the ongoing OASISplus study (NCT05392114), which is designed to evaluate the long-term safety and efficacy of donidalorsen treatment.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.1-2"></a>

###### Switch cohort objective

> “The Switch cohort of the OASISplus study (NCT05392114) evaluated the long‐term safety and efficacy of donidalorsen in patients who switched from a long‐term prophylactic treatment (LTP) to donidalorsen with 1‐year outcomes.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Registered study dates and enrollment status

| Field | Reported value |
| --- | --- |
| Study start | “2022-07-13” |
| Primary completion, estimated | “2026-12” |
| Study completion, estimated | “2027-03” |
| Recruitment status | “Active, not recruiting” |

Source: [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

<a id="topic-3.1.5.2-2"></a>

###### Data cutoff for the year 1 analyses

> “This prespecified analysis of the ongoing OASISplus study reports results for patients who completed the OLE through Week 52 (including 28 additional days of follow-up, defined as the on-treatment period) as of a January 27, 2025 data cut.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

> “OASISplus is an ongoing, global, open‐label study designed to evaluate the long‐term safety and efficacy of donidalorsen 80 mg administered SC in patients with HAE‐C1INH‐Type1 and HAE‐C1INH‐Type2”
> “(data cutoff date: January 27, 2025)”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Open-label, single-group design with two cohorts

> “An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)”

Source: [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

> “OASISplus is an ongoing multicenter, phase 3 study composed of 2 cohorts: a de novo cohort of patients who switched from prior LTPs to donidalorsen 80 mg Q4W (Switch cohort), and an OLE cohort of patients who rolled over from the OASIS-HAE study.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Open-label extension cohort: rollover from OASIS-HAE

> “Patients were eligible to enroll in the OLE if they successfully completed the OASIS-HAE study or if they had five or more attacks/month for two consecutive months after Week 4 of OASIS-HAE, in which case they could rollover early into the OLE and receive donidalorsen Q4W”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.4-2"></a>

###### Switch cohort: age and stable prior prophylaxis

> “Participants must be aged ≥ 12 years at the time of informed consent and, as applicable, assent.”
> “Participants must be on a stable dose (≥ 12 weeks) of prophylaxis treatment with lanadelumab or berotralstat or SC C1-esterase inhibitor prior to the Screening Period.”

Source: [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

> “the Switch cohort included adults and adolescents aged ≥ 12 years on stable prophylactic doses of plasma‐derived or recombinant C1INH via SC or intravenous (IV) administration, lanadelumab, or berotralstat.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="topic-3.1.5.4-3"></a>

###### Switch cohort: exclusions for concomitant medicines and prior oligonucleotides

> “Participated in a prior donidalorsen study.”
> “Angiotensin-converting enzyme (ACE) inhibitors or any estrogen containing medications with systemic absorption.”
> “Oligonucleotides (including small interfering ribonucleic acid”
> “within 4 months of Screening if single dose received, or within 12 months of Screening if multiple doses received.”

Source: [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Open-label extension cohort: assignment to every-4-week or every-8-week dosing

> “Patients who received donidalorsen 80 mg or placebo Q4W in OASIS-HAE received donidalorsen 80 mg Q4W in OASISplus.”
> “Patients who received donidalorsen 80 mg or placebo Q8W in OASIS-HAE received donidalorsen 80 mg Q8W in OASISplus, unless they were not attack-free during the last 8 weeks (Weeks 16–24) in OASIS-HAE, in which case they received donidalorsen Q4W in OASISplus.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.5-2"></a>

###### Switch cohort: transition algorithm from prior prophylaxis

> “patients were switched from their prior LTP administered during the baseline period to donidalorsen 80 mg administered SC Q4W with no washout period using a prespecified algorithm that was designed to minimize HAE attacks during the switching process”
> “Patients who received prior lanadelumab received their last dose 14 ± 3 days prior to the first dose of donidalorsen on Day 1 of the study, and patients who received prior berotralstat or C1INH continued the treatment for 14 ± 3 days after Day 1 of the study.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="topic-3.1.5.5-3"></a>

###### Planned treatment duration

> “Group 1 and Group 2 participants will be administered donidalorsen by SC injection for up to 157 weeks.”

Source: [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Treatment-emergent Adverse Event Incidence as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Primary endpoint: incidence and severity of treatment-emergent adverse events

> “Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by Severity”

Source: [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

> “The primary endpoint was the incidence of TEAEs, as defined by the Medical Dictionary for Regulatory Activities System Organ Class, and TEAE severity.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

> “The primary endpoint was the incidence and severity of treatment‐emergent adverse events (TEAEs) and their relation to donidalorsen treatment.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="topic-3.1.5.6.1-2"></a>

###### Secondary endpoints: attack rate and angioedema quality of life

> “Rates of HAE attacks were time-normalized per every 4-week period (28 days), also termed monthly.”
> “AE-QoL is a validated, 17-item, disease-specific, self-administered questionnaire with four domains calculated using a scale of 0 to 100, with lower scores indicating better QoL, and a minimal clinically important difference of ≥6 points.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.6.1-3"></a>

###### Switch cohort: attack-rate baseline measured on prior prophylaxis

> “Baseline for the HAE attack rate endpoint in this study was the time from the 10‐week screening period to study Day 1, and was Day 1 for all other endpoints.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="topic-3.1.5.6.1-4"></a>

###### Exploratory endpoint: disease control on the Angioedema Control Test

> “Scores of 10 or higher indicate well-controlled disease.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Registered enrollment

| Population | Participants |
| --- | --- |
| Actual enrollment, both cohorts | “154” |

Source: [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

<a id="topic-3.1.5.7.1-2"></a>

###### Open-label extension cohort

> “The OLE cohort included 83 patients (Q4W, n=69 [83%]; Q8W, n=14 [17%]).”
> “No formal sample size calculations were performed”
> “The sample size for the OLE cohort was dictated by the number of patients enrolled in the OASIS-HAE study and their eligibility for the study.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.7.1-3"></a>

###### Switch cohort by prior prophylactic treatment

> “A total of 65 patients were enrolled in the original cohort, and of these, 64 (98.5%) patients received at least one dose of donidalorsen (prior lanadelumab, n = 31; prior berotralstat, n = 11; prior C1INH, n = 22 [SC, n = 15; IV, n = 7])”
> “The Switch cohort sample size was instead determined per clinical assessment.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Open-label extension cohort: safety and full analysis sets

> “results were summarized with descriptive statistics including observed mean, median, patient numbers, and percentages.”
> “All endpoints were analyzed using data from the safety and full analysis sets, both defined as all patients who received at least one dose of donidalorsen.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.7.2-2"></a>

###### Switch cohort: descriptive analysis without a comparator group

> “As OASISplus was an open‐label study in which all patients received donidalorsen, no comparator group and no formal sample size calculations were performed to address group differences.”
> “The safety set was used for the primary outcome and all safety analyses. The efficacy endpoints were summarized using descriptive statistics in the full analysis set.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Open-label extension cohort: completion and discontinuation at year 1

> “As of the data cutoff date (January 27, 2025), 75 patients (90%) completed Week 52 in the OLE study. Eight patients (10%) discontinued treatment early due to voluntary withdrawal (n = 4), AEs (n = 3), or pregnancy (n = 1; Supplemental Table 1).”
> “six patients changed from donidalorsen Q8W in OASIS-HAE to Q4W dosing in OASISplus, and 19 patients from the OASIS-HAE placebo group were assigned to receive donidalorsen Q4W”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.1-2"></a>

###### Switch cohort: completion and discontinuation at year 1

> “54 (83.1%) patients completed 1 year of treatment”
> “A total of 11 (16.9%) patients discontinued donidalorsen treatment, including 8 (12.3%) patients who switched from lanadelumab and 3 (4.6%) patients who switched from SC or IV C1INH.”
> “In patients who received lanadelumab before switching to donidalorsen, the most common reason for treatment discontinuation was lack of efficacy (n = 4)”
> “No patients who received prior berotralstat therapy discontinued treatment.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Open-label extension cohort: demographics and baseline attack rate

| Characteristic, total (N=83) | Reported value |
| --- | --- |
| Age, years, mean (SD) | “37 (14)” |
| Age 12 to 17 years, n (%) | “7 (8.4)” |
| Female, n (%) | “45 (54.2)” |
| White, n (%) | “76 (91.6)” |
| Baseline HAE attack rate, mean (SD) | “3.4 (2.1)” |

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.2-2"></a>

###### Switch cohort: demographics and baseline attack rate on prior prophylaxis

| Characteristic, total (N=64) | Reported value |
| --- | --- |
| Age, years, mean (SD) | “42 (15)” |
| Age 12 to 17 years, n (%) | “4 (6.3)” |
| Female, n (%) | “38 (59.4)” |
| White, n (%) | “57 (89.1)” |
| Baseline HAE attack rate, mean (SD) | “0.9 (1.3)” |

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Open-label extension cohort: reduction in attack rate from OASIS-HAE baseline, weeks 0 to 52

> “The mean reduction in HAE attack rate over the 52-week OLE was 94% (median, 98%) in the Q4W group (including patients who moved from Q8W dosing in OASIS-HAE to Q4W in the OLE) and 95% (median, 96%) in the donidalorsen Q8W group.”
> “This corresponded to a reduction in mean (SD) time-normalized monthly HAE attack rate from 3.5 (2.13) and 2.9 (2.06) at baseline to 0.3 (0.45) and 0.1 (0.10) over Weeks 0 to 52 in the Q4W and Q8W dosing groups, respectively.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.3-2"></a>

###### Open-label extension cohort: attack-free participants, weeks 4 to 52

> “A total of 48% (Q4W) and 29% (Q8W) were attack-free during the same period”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.3-3"></a>

###### Switch cohort: change in attack rate from baseline on prior prophylaxis, weeks 0 to 52

> “Overall, HAE attack rates decreased by 67.6% from a mean (SD) of 0.85 (1.3) at baseline (on their prior HAE prophylactic therapy) to 0.28 (0.4) over the treatment period through 1 year (Weeks 0–52) of the study”
> “Patients who switched from lanadelumab experienced a 63.9% decrease, patients who switched from berotralstat experienced an 83.1% decrease, and patients who switched from C1INH experienced a 50.7% decrease in HAE attack rate from baseline.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

###### Open-label extension cohort: AE-QoL and disease control at week 52

> “The mean (SD) reduction from baseline in AE-QoL total score at Week 52 was 27.8 (16.1) points overall, 28.1 (15.7) points in the Q4W group, and 26.7 (18.2) points in the Q8W group.”
> “68 of 70 (97%) patients with an AECT evaluation at both OASIS-HAE baseline and OASISplus Week 52 reported well-controlled disease (AECT score ≥10)”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.4-2"></a>

###### Switch cohort: AE-QoL, disease control, and treatment satisfaction at week 52

> “AE‐QoL total score improved by a mean (SD) of 12.2 (17.6) points from baseline to Week 52 in the overall population”
> “Overall, after 52 weeks of treatment with donidalorsen, 90.4% of patients had well‐controlled disease (prior lanadelumab, n/N = 18/22 [81.8%]; prior berotralstat, n/N = 10/10 [100%]; prior C1INH, n/N = 19/20 [95.0%]; Figure 3).”
> “The overall mean (SD) global satisfaction domain score on the TSQM‐II improved from 75.7 (21.5) at baseline to 89.4 (15.3) at Week 52”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Open-label extension cohort: treatment-emergent adverse events at year 1

| Event, total (N=83) | Participants, n (%) |
| --- | --- |
| Any TEAE | “75 (90.4)” |
| TEAE related to study drug | “22 (26.5)” |
| TEAE leading to discontinuation | “3 (3.6)” |
| Any serious TEAE | “7 (8.4)” |

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.5-2"></a>

###### Open-label extension cohort: serious events, liver enzymes, and bleeding

> “Seven (8%) patients, all of whom received donidalorsen Q4W, reported serious AEs; none were considered drug related.”
> “One patient in the Q4W group died by suicide, considered unrelated to treatment.”
> “the other had a 30-day persistence of alanine aminotransferase levels at >5 times the upper limit of normal (ULN) with normal blood bilirubin concentration that resolved after treatment discontinuation.”
> “There were no major bleeding events or treatment-related trends in activated partial thromboplastin time observed during the treatment period.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.5-3"></a>

###### Open-label extension cohort: hypersensitivity reaction after year 1

> “one patient experienced a serious type 1 hypersensitivity reaction characterized by rash, dyspnea, perioral swelling, and chest pain after receiving the 29th dose of donidalorsen Q4W (being on this regimen for approximately 2.5 years).”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.5-4"></a>

###### Switch cohort: treatment-emergent adverse events at year 1

| Event, total (N=64) | Participants, n (%) |
| --- | --- |
| Any TEAE | “56 (87.5)” |
| TEAE related to study drug | “24 (37.5)” |
| TEAE leading to discontinuation | “1 (1.6)” |
| Any serious TEAE | “1 (1.6)” |

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="topic-3.1.5.8.5-5"></a>

###### Switch cohort: most common treatment-related adverse events

> “The most common treatment‐related AEs occurring in more than 5% of the overall population were injection‐site erythema (10.9%), injection‐site pruritus (10.9%), injection‐site pain (7.8%), and fatigue (7.8%).”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="topic-3.1.5.8.5-6"></a>

###### Immunogenicity in the open-label extension

> “In an open-label extension trial, patients that rolled over from OASIS-HAE continued treatment with DAWNZERA in the 80 mg every 4 weeks or every 8 weeks groups for up to 3 years (median exposure duration of 227 days).”
> “The incidence rate of treatment-emergent ADAs was 35% (22 of 63 patients) in the DAWNZERA 80 mg every 4 weeks group”
> “The incidence rate of treatment-emergent ADAs was 21% (3 of 14 patients) among patients who received DAWNZERA 80 mg every 8 weeks in OASIS-HAE and open-label extension.”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

OASISplus is an open-label study with no comparator group, and both cohort publications summarized outcomes with descriptive statistics and no formal sample size calculation.

The open-label extension cohort enrolled 83 of the 90 OASIS-HAE participants (69 receiving donidalorsen every 4 weeks and 14 every 8 weeks). Participants continued every-8-week dosing only if they had been attack-free during the last 8 weeks of OASIS-HAE, so the every-8-week group of 14 participants was selected for response. The 94% and 95% reductions are measured from the OASIS-HAE baseline, before any prophylaxis in that trial.

The Switch cohort dosed 64 participants who had been receiving lanadelumab (31), berotralstat (11), or C1 inhibitor (22). Its attack-rate baseline was the screening period on the prior prophylactic treatment (mean 0.85 attacks per month), so the 67.6% reduction is a within-participant comparison with continued prior prophylaxis, without randomization or blinding. Eleven participants (16.9%) discontinued during the first year, including 4 who had switched from lanadelumab and discontinued for lack of efficacy. The subgroups by prior therapy contain 11 to 31 participants, which limits precision for comparisons between them.

In both cohorts, 89.1% to 91.6% of participants were White. The registry lists an actual enrollment of 154 participants across the study, and the two cohort publications report 83 and 65 participants enrolled. The year 1 publications report data through January 27, 2025, and the registry lists treatment for up to 157 weeks, with primary completion estimated for December 2026.

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/); [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/); [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

<a id="heading-3.1.6"></a>

#### 3.1.6 HELP

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Prevention objective

> “preventing hereditary angioedema attacks.”

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Study sites

> “41 sites”

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Parallel-group design

> “randomized, double-blind, parallel-group, placebo-controlled”

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Age eligibility

> “Patients aged ≥ 12 years”

Source: [Lumry et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/all.14680)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Subcutaneous lanadelumab regimens; placebo comparator

| Regimen | Dose and interval |
| --- | --- |
| Lower-dose monthly | “150 mg q4wks” |
| Higher-dose monthly | “300 mg q4wks” |
| Every two weeks | “300 mg q2wks” |

Source: [FDA (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Monthly HAE Attack Rate as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Primary clinical endpoint

> “number of investigator-confirmed attacks of hereditary angioedema”

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Randomized treatment groups

| Group | Participants |
| --- | --- |
| Lanadelumab 150 mg every four weeks | “28” |
| Lanadelumab 300 mg every four weeks | “29” |
| Lanadelumab 300 mg every two weeks | “27” |
| Placebo | “41” |

Source: [Lumry et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/all.14680)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Primary analysis population and model

> “Intent-to-Treat”
> “Poisson regression model”

Source: [FDA (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf)

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Study completion

| Disposition | Participants, n (%) |
| --- | --- |
| Completed | “113 (90.4%)” |

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Age at baseline

| Characteristic | Reported value |
| --- | --- |
| Mean age, years | “40.7” |

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Mean monthly attack rate over 26 weeks

| Treatment | Attacks per month |
| --- | --- |
| Lanadelumab 150 mg every four weeks | “0.48” |
| Lanadelumab 300 mg every four weeks | “0.53” |
| Lanadelumab 300 mg every two weeks | “0.26” |
| Placebo | “1.97” |

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.6.8.4-1"></a>

###### Participants achieving the AE-QoL minimal clinically important difference

| Population | Proportion |
| --- | --- |
| All lanadelumab regimens pooled | “70%” |
| Placebo | “37%” |
| Lanadelumab 300 mg every two weeks | “81%” |

Source: [Lumry et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/all.14680)

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Injection-site reactions

| Treatment | Participants, n (%) |
| --- | --- |
| Lanadelumab 150 mg every four weeks, n=28 | “16 (57)” |
| Lanadelumab 300 mg every four weeks, n=29 | “13 (45)” |
| Lanadelumab 300 mg every two weeks, n=27 | “15 (56)” |
| Placebo, n=41 | “14 (34)” |

Source: [FDA (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

The trial randomized 125 participants to three lanadelumab regimens (28, 29, and 27 participants) or placebo (41 participants), and 113 (90.4%) completed the study. The primary analysis used the “Intent-to-Treat” population and a “Poisson regression model”. Because three active regimens shared the randomization, each lanadelumab group contained 27 to 29 participants, which limits precision for comparisons between regimens and for uncommon adverse events; injection-site reactions were reported in 45% to 57% of lanadelumab groups and in 34% of the placebo group. The placebo-controlled period does not describe outcomes over longer treatment. Lanadelumab was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, run-in requirements, baseline attack rates, and observation periods can affect the reported attack rates.

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/); [Lumry et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/all.14680); [FDA (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf)

<a id="heading-3.1.7"></a>

#### 3.1.7 VANGUARD

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

###### Prophylactic treatment objective

> “prophylactic treatment for attacks due to hereditary angioedema (HAE).”

Source: [CSL (2023)](https://newsroom.csl.com/2023-03-01-The-Lancet-Publishes-Pivotal-Phase-3-Data-on-CSLs-First-in-Class-Garadacimab-for-HAE)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Number of trial centers

> “28 centers”

Source: [FDA Drug Trials Snapshot ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Study design and allocation ratio

> “randomised, double-blind, placebo-controlled”
> “(3:2)”

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Eligibility: age and run-in attacks

> “12 years of age and older”
> “two or more acute HAE attacks”

Source: [FDA Drug Trials Snapshot ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Administration schedule

> “monthly subcutaneous injections of garadacimab”

Source: [CSL (2023)](https://newsroom.csl.com/2023-03-01-The-Lancet-Publishes-Pivotal-Phase-3-Data-on-CSLs-First-in-Class-Garadacimab-for-HAE)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Monthly HAE Attack Rate as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

###### Primary endpoint: six-month observation

> “number of HAE attacks per month”

Source: [FDA Drug Trials Snapshot ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry)

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Randomized and included populations

| Population | Participants |
| --- | --- |
| Randomized | “65” |
| Garadacimab included | “39” |
| Placebo included | “25” |

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

###### Safety population: minimum treatment exposure

> “at least one dose”

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

<a id="topic-3.1.7.8.1-1"></a>

###### Randomization error

> “One patient was randomly assigned in error”

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

###### Baseline sex distribution

| Characteristic | Participants, n (%) |
| --- | --- |
| Female | “38 (59%)” |

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### Published monthly attack rates and relative treatment effect

| Outcome | Reported value |
| --- | --- |
| Garadacimab: mean monthly attack rate | “0·27” |
| Placebo: mean monthly attack rate | “2·01” |
| Difference in means, percent | “-87%” |

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.7.8.4-1"></a>

###### AE-QoL total score by attack-free status: post hoc analysis

> “Patients ages ≥ 18 years completed the Angioedema Quality of Life (AE-QoL) questionnaire in both studies; scores were evaluated post hoc by attack-free status.”
> “In the pivotal phase III and phase III OLE studies, 62% and 60% of patients, respectively, were attack-free.”
> “In the pivotal phase III study, the mean AE-QoL total score improved with garadacimab, from 38.8 (day 1) to 6.6 (month 6) for attack-free patients (n = 19) and to 18.4 for patients with one or more attacks (n = 14) versus a change in mean AE-QoL total score from 43.7 to 40.5 with placebo (n = 20).”

Source: [Staubach et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40380356/)

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Nasopharyngitis adverse reactions

| Treatment | Participants, n (%) |
| --- | --- |
| Garadacimab, n=39 | “8 (21)” |
| Placebo, n=25 | “3 (12)” |

Source: [FDA Drug Trials Snapshot ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary

Of 65 randomized participants, 64 were included in the reported comparison (39 receiving garadacimab and 25 receiving placebo) after one participant was randomized in error. Allocation was 3:2 across 28 centers, and the placebo group of 25 participants limits precision for between-group estimates and for uncommon adverse events. Eligibility required “two or more acute HAE attacks”. The primary endpoint, the number of HAE attacks per month, does not describe outcomes over longer treatment. No health-related quality of life result for this trial was identified. Garadacimab was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, run-in requirements, baseline attack rates, and observation periods can affect the reported attack rates.

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/); [FDA Drug Trials Snapshot ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry); [CSL (2023)](https://newsroom.csl.com/2023-03-01-The-Lancet-Publishes-Pivotal-Phase-3-Data-on-CSLs-First-in-Class-Garadacimab-for-HAE)

<a id="heading-3.1.8"></a>

#### 3.1.8 APeX-2

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

###### Treatment evaluation objective

> “efficacy, safety, and tolerability”

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

###### Trial geography

> “40 sites in 11 countries”

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Study design

> “multicenter, randomized, double-blind, placebo-controlled, parallel-group study”

Source: [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

###### Run-in attack requirement

> “at least two investigator-confirmed attacks”

Source: [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

###### Berotralstat 110-mg and 150-mg regimens: route and administration

> “oral administration once daily, with food”

Source: [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using Monthly HAE Attack Rate as the Primary Endpoint

Not applicable.

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Randomized and treated populations

| Population | Participants |
| --- | --- |
| Randomized | “121” |
| Berotralstat 110 mg treated | “41” |
| Berotralstat 150 mg treated | “40” |
| Placebo treated | “39” |

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

<a id="topic-3.1.8.7.2-1"></a>

###### Efficacy population and model

> “Intent-to-Treat (ITT) population”
> “negative binomial regression model”

Source: [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

<a id="topic-3.1.8.8.1-1"></a>

###### Treatment exposure

| Population | Participants |
| --- | --- |
| Received at least one dose | “120” |

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

<a id="topic-3.1.8.8.2-1"></a>

###### Median baseline attack rate during the prospective run-in period

> “2.9/month”

Source: [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

###### Monthly attack rates during the 24-week comparison

| Treatment | Attacks per month |
| --- | --- |
| Berotralstat 110 mg | “1.65” |
| Berotralstat 150 mg | “1.31” |
| Placebo | “2.35” |

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.8.8.4-1"></a>

###### AE-QoL total score at week 24 in APeX-2

> “In both APeX‐2 and APeX‐J, 43% of patients receiving berotralstat 150 mg achieved minimal clinically important difference (MCID) in Angioedema QoL (AE‐QoL) total score, compared with 17% in the placebo group at 6 months”
> “least square mean difference [LSMD] of change from baseline: −4.9 in APeX‐2 [p = 0.188]”

Source: [Caballero et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13327139/)

<a id="topic-3.1.8.8.4-2"></a>

###### Pooled APeX-2 and APeX-J post hoc analysis: AE-QoL at week 24

> “We conducted a post hoc trial analysis to evaluate the impact of berotralstat on HRQoL versus placebo through 24 weeks, and the long‐term effects of treatment up to 96 weeks, using pooled APeX‐2 and APeX‐J patient data.”
> “A total of 47 patients treated with berotralstat (40 from APeX‐2; 7 from APeX‐J) and 45 treated with placebo (39 from APeX‐2; 6 from APeX‐J) were included in the analysis.”
> “At Week 24, patients receiving berotralstat demonstrated significantly greater improvement versus placebo in AE‐QoL total (LSMD: −7.4; 95% CI: −14.3, −0.6; p < 0.05), functioning domain (LSMD: −10.9; 95% CI: −19.6, −2.3; p = 0.013), and fears/shame domain (LSMD: −8.7; 95% CI: −17.2, −0.2; p = 0.046) scores.”

Source: [Caballero et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13327139/)

<a id="topic-3.1.8.8.4-3"></a>

###### Open-label extension: quality of life through 96 weeks

> “Secondary endpoints included HAE attack rates and quality of life (QoL).”
> “Clinically meaningful improvements in QoL were also observed, with the largest improvements in the functioning domain.”

Source: [Kiani-Alikhan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38122865/)

> “Among patients receiving berotralstat, consistent sustained improvements were observed across all AE‐QoL domains up to Week 96.”

Source: [Caballero et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13327139/)

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

<a id="topic-3.1.8.8.5-1"></a>

###### Serious treatment-emergent adverse events considered drug related

> “No drug-related serious treatment-emergent adverse events occurred.”

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary

The trial randomized 121 participants at 40 sites in 11 countries and treated 120: 41 received berotralstat 110 mg, 40 received berotralstat 150 mg, and 39 received placebo. Eligibility required “at least two investigator-confirmed attacks” during the run-in period, and the median baseline attack rate was 2.9 attacks per month. Efficacy was analyzed in the intent-to-treat population with a “negative binomial regression model”. The comparison does not describe outcomes over longer treatment, and groups of 39 to 41 participants limit precision for uncommon adverse events. No health-related quality of life result for this trial was identified. Berotralstat was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, baseline attack rates, and observation periods can affect the reported attack rates.

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/); [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.9"></a>

#### 3.1.9 COMPACT

<a id="heading-3.1.9.1"></a>

##### 3.1.9.1 Objective

<a id="topic-3.1.9.1-1"></a>

###### Clinical objective

> “clinical efficacy of SC CSL830 in the prophylactic treatment of HAE”

Source: [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)

<a id="heading-3.1.9.2"></a>

##### 3.1.9.2 Location and Study Date

<a id="topic-3.1.9.2-1"></a>

###### Trial locations and global end date

| Field | Reported value |
| --- | --- |
| Planned region | “Argentina” |
| Planned region | “Australia” |
| Planned region | “Canada” |
| Planned region | “European Union” |
| Planned region | “United States” |
| Global end of trial | “2015-10-12” |

Source: [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)

<a id="heading-3.1.9.3"></a>

##### 3.1.9.3 Study Design

<a id="topic-3.1.9.3-1"></a>

###### Crossover design

> “32-week, multicenter, randomized, double-blind, placebo-controlled, crossover study”

Source: [CSL Behring (2026)](https://www.haegarda.com/hcp/efficacy)

<a id="heading-3.1.9.4"></a>

##### 3.1.9.4 Eligibility Criteria

<a id="topic-3.1.9.4-1"></a>

###### Age eligibility

> “12 years or older”

Source: [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)

<a id="heading-3.1.9.5"></a>

##### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

###### Subcutaneous regimens and frequency

> “60 IU/kg”
> “40 IU/kg”
> “twice weekly (every 3 or 4 days)”

Source: [CSL Behring (2026)](https://www.haegarda.com/hcp/efficacy)

<a id="heading-3.1.9.6"></a>

##### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

###### 3.1.9.6.1 Rationale for Using HAE Attack Frequency as the Primary Endpoint

<a id="topic-3.1.9.6.1-1"></a>

###### Primary clinical endpoint

> “number of attacks of angioedema.”

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)

<a id="heading-3.1.9.7"></a>

##### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

###### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.9.7.1-1"></a>

###### Planned enrollment

| Population | Participants |
| --- | --- |
| Whole trial | “100” |

Source: [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)

<a id="topic-3.1.9.7.1-2"></a>

###### Actual randomization

| Population | Participants |
| --- | --- |
| Randomized | “90” |

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)

<a id="heading-3.1.9.7.2"></a>

###### 3.1.9.7.2 Description of Analysis Sets

<a id="topic-3.1.9.7.2-1"></a>

###### Efficacy evaluation window

> “Efficacy was evaluated for the last 14 weeks of each treatment period.”

Source: [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf)

<a id="heading-3.1.9.8"></a>

##### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

###### 3.1.9.8.1 Participant Disposition

<a id="topic-3.1.9.8.1-1"></a>

###### Study completion

| Disposition | Participants |
| --- | --- |
| Completed | “79” |

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)

<a id="heading-3.1.9.8.2"></a>

###### 3.1.9.8.2 Baseline Characteristics

<a id="topic-3.1.9.8.2-1"></a>

###### Baseline age

| Characteristic | Reported value |
| --- | --- |
| Median age, years (range) | “40 (12 to 72)” |

Source: [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf)

<a id="heading-3.1.9.8.3"></a>

###### 3.1.9.8.3 Efficacy Results

<a id="topic-3.1.9.8.3-1"></a>

###### Monthly attack-rate differences versus placebo

| Regimen | Mean difference, attacks per month |
| --- | --- |
| 40 IU/kg twice weekly | “-2.42” |
| 60 IU/kg twice weekly | “-3.51” |

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)

<a id="heading-3.1.9.8.4"></a>

###### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.9.8.4-1"></a>

###### Post hoc HRQoL analysis: instruments and timing

> “Post hoc analysis of data from the placebo-controlled, crossover phase III COMPACT study”
> “HRQoL assessments at week 14 (last visit) included the European Quality of Life-5 Dimensions Questionnaire (EQ-5D-3L), the Hospital Anxiety and Depression Scale (HADS), the Work Productivity and Activity Impairment Questionnaire (WPAI), and the Treatment Satisfaction Questionnaire for Medication (TSQM).”

Source: [Lumry et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29391286/)

<a id="topic-3.1.9.8.4-2"></a>

###### HRQoL during subcutaneous C1-INH compared with placebo

> “Compared with placebo (on-demand treatment alone), treatment with twice weekly C1-INH(SC) (both doses combined) was associated with better EQ-5D visual analog scale general health, less HADS anxiety, less WPAI presenteeism, work productivity loss, and activity impairment, and greater TSQM effectiveness and overall treatment satisfaction.”
> “For each HRQoL measure, a greater proportion of patients had a clinically meaningful improvement during C1-INH(SC) treatment compared with placebo.”

Source: [Lumry et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29391286/)

<a id="heading-3.1.9.8.5"></a>

###### 3.1.9.8.5 Safety Results

<a id="topic-3.1.9.8.5-1"></a>

###### Most common adverse events

> “mild and transient local site reactions”

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)

<a id="heading-3.1.9.9"></a>

##### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

###### Summary

The crossover trial randomized 90 participants against a planned enrollment of 100, and 79 participants completed it. Each participant received active treatment and placebo in sequence, and efficacy was evaluated “for the last 14 weeks of each treatment period” of the 32-week study, so period and carryover effects can influence the estimates. The efficacy results reported for this trial are mean differences from placebo in monthly attack rate (-2.42 attacks per month with 40 IU/kg and -3.51 with 60 IU/kg twice weekly), which are not directly comparable with absolute attack rates reported for parallel-group designs. No health-related quality of life result for this trial was identified. The trial enrolled participants aged 12 years or older, with a median age of 40 years (range, 12 to 72). Subcutaneous C1 inhibitor was compared with placebo only, so comparison with other prophylactic agents relies on cross-trial comparison.

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/); [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf); [CSL Behring (2026)](https://www.haegarda.com/hcp/efficacy); [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
